St. Joseph Cancer Center - Clinical Trials: Breast
  

Early Stage:

  • None currently

Stage 0, I, or II:

  • RTOG 0413: A Randomized Phase III Study of Conventional Whole Breast Irradiation vs Partial Breast Irradiation for Women with Stage 0, I, or II Breast Cancer

T1-3, Node Negative:

  • CTSU C40101: Cyclosphosphamide and Doxorubicin (CA x 4 Cycles) Versus Paclitaxel (4 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes
     

  • CTSU PACCT-1: Program for the Assessment of Clinical Trial Tests (PACCT-1):
    Trial Assigning Individualized Options for Treatment: The TAYLORx Trial

Stage I, II, III:

  • CTSU 25-02: A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer
     

  • SWOG 0221: Phase III Trial of Continuous Schedule AC + G vs Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer
     

  • SWOG 0230: Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Standard Adjuvant Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
     

  • CTSU 24-02: Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer. (SOFT Trial)
     

  • NSABP B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer
     

  • CTSU N063D:  Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) study: A Randomised, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer
     

  • NSABP B-41: A randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trasturzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response

Stage II, III:

  • CTSU C40601: Randomized Phase III Trial of Paclitaxel Combined with Trastuzumab, Lapatinib, or Both as Neoadjuvant Treatment of Her2-Positive Primary Breast Cancer

Stage IV:

  • SWOG 0500: A Randomized Phase III Trial to test the Strategy of Changing therapy Versus Maintaining Therapy for Metastatic Breast cancer Patients who have Elevated Circulating Tumor Cells at First Follow-Up Assessment
     

  • CTSU C40302:  Endocrine Therapy with or without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or without Lapatinib (GW572016) for Postmenopausal Women with Estrogen-Receptor Positive Advanced Breast Cancer
     

  • CTSU E1105: A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer
     

  • NSABP B-43: A Phase III Clinical Trial Comparing Trastumab Given Concurrently with Radiation therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy

For more information on the above clinical trials: Cheryl Patz, RN, OCN, CCRC, 360.715.4133

Return to previous page

Cancer Services

Cancer Committee

Cancer Program